We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New AI-Driven COVID-19 Testing Algorithm Could Lead to Fewer Infections

By LabMedica International staff writers
Posted on 25 Jan 2021
A new artificial intelligence (AI) algorithm could help leaders of governments and organizations make better informed decisions on how many symptomatic and asymptomatic individuals to test for COVID-19 with a limited supply of daily tests, and at what stage of the pandemic.

Simulated testing strategies of the AI model developed by researchers at Penn State’s College of Information Sciences and Technology (University Park, PA, USA) resulted in approximately 40% fewer infections. More...
Using an AI model known as Partially Observable Markov Decision Processes, the team developed a sequential policy for distributing tests among a population. Their model, called Design of Optimal COVID-19 Testing Oracle, or DOCTOR, was measured against other existing testing strategies used by governments and institutions. Many of these other strategies are static and non-adaptive, potentially causing significant shortcomings in their effectiveness in containing COVID-19.

In a two-phased approach, DOCTOR first suggests spending more effort in testing symptomatic individuals, allocating approximately 65% of its available testing kits for individuals presenting symptoms. Over time, as the number of symptomatic individuals diminishes due to these patients moving to quarantine or hospital settings, DOCTOR shifts its attention to asymptomatic testing, gradually increasing the number of testing kits allocated to asymptomatic individuals as decision points proceed. When applied in a simulation to the city of Santiago in Panama - a country with the world’s highest rate of COVID-19 infections per capita - the model’s testing strategy outperformed state-of-the-art baselines by achieving approximately 40% fewer COVID-19 infections. This illustrates the benefit of having an adaptive strategy, and even more so with new variants of the virus emerging, according to the researchers. The team’s research shows that the use of an AI-driven testing strategy for COVID-19 would be most beneficial when the pandemic spread is intermediate - meaning it’s not too severe and it’s not too slow. As COVID-19 is currently in an intermediate stage in many places worldwide, it is an optimal time for governments and institutions to consider an AI-driven testing strategy. Additionally, the model could be useful in guiding decision makers in the event of a future pandemic.

“There is a possibility that testing is still going to be a part of our COVID-19 prevention efforts in the next year,” said Amulya Yadav, PNC Technologies Career Development Assistant Professor at the College of IST. “Even if vaccines work on the new variants as well, I think there is going to be a difference or a divide between developed and underdeveloped countries and how quickly they are able to vaccinate their populations. So testing is going to be much more important.”

Related Links:
Penn State


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.